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BNCT is a tumour treatment based on thermal-neutron irradiation of tissues 
enriched with 10B, which according to the 10B(n, )7Li reaction produces 
particles with high Linear Energy Transfer and short range. Since this 
treatment can deliver a therapeutic tumour dose sparing normal tissues, 
BNCT represents an alternative for diffuse tumours and metastases, which 
show poor response to surgery and photontherapy. In 2001 and 2003, in 
Pavia BNCT was applied to an isolated liver, which was infused with boron, 
explanted, irradiated and re-implanted. A new project was then initiated for 
lung tumours, developing a protocol for Boron concentration measurements 
and performing organ-dose Monte Carlo calculations; in parallel, 
radiobiology studies are ongoing to characterize the BNCT effects down to 
cellular level. After a brief introduction, herein we will present the main 
activities ongoing in Pavia including the radiobiological ones, which are 
under investigation not only experimentally but also theoretically, basing on 





“The difficulties disappear, however, if it be assumed that the radiation consists of particles of mass 1 
and charge 0, or neutrons” [1]. Only four years after the neutron discovery by Sir James Chadwick, 
Locher provided a detailed description of the biological effects expected from neutron irradiation and 
proposed to use the neutron capture reaction on 10B for therapeutic purposes [2]. More specifically he 
cited „„the possibility of destroying or weakening cancerous cells, by the general or selective 
absorption of neutrons by these cells. In particular there exist the possibilities of introducing small 
quantities of neutron absorbers into the regions where it is desired to liberate ionizing energy. A 
simple illustration would be the injection of a soluble non-toxic compound of boron, lithium, 
gadolinium or gold into a superficial cancer, followed by bombardment with slow neutrons‟‟. Boron 
Neutron Capture Therapy (BNCT) is indeed an experimental radiotherapy based on thermal neutron 
irradiation of tumour cells previously enriched with 10B, which has a very high cross section (3837 
barn at thermal energies) for the 10B(n, )7Li reaction. This reaction gives rise to an alpha particle and a 
Li ion of short range (9 and 5 m, respectively), which deposit most of their energy in the same cell 
where they were produced. BNCT can be a valid option to treat patients affected by tumours that are 
not surgically operable and do not show positive response to chemotherapy nor to conventional 
radiotherapy, such as diffuse primary tumours and metastatic disseminations. The selective Boron 
uptake by the tumour cells is one of the key issues of BNCT, since it allows delivering a potentially 
therapeutic dose to the tumour with a substantial sparing of the surrounding normal tissues.  
     The history of BNCT has been long and sometimes complicated. The first clinical applications took 
place at the beginning of the 1950s in the USA at BNL and MIT for cerebral gliomas, which were 
treated with a borated compound named Borax and irradiated with reactor thermal neutrons [3]. The 
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outcomes were not satisfactory, mainly due to the low penetration of thermal neutrons and the low 
selectivity of the Borated compound; the trials were stopped in 1959. Better results were obtained in 
the late 1960s in Japan, thanks to new compounds with higher selectivity [4]. Although in terms of 
survival the results were not better than those with conventional radiotherapy, the high number of 
treated patients (120) was a great stimulus for the researchers to continue. In 1994 a new clinical trial 
started at BNL in Brookhaven, where the use of epithermal neutrons allowed to achieve a better 
penetration, sparing the skin and delivering a higher dose to the tumour, thanks to the neutron 
thermalization in the first tissue layers (skin and scalp) [5,6]. Furthermore, a new generation of borated 
compounds was developed such as BPA-f (boronophenylalanine-fructose complex), which is able to 
carry the Boron atoms inside the cells penetrating the cell membranes. In the same period, a trial for 
cutaneous melanoma and another one on intra-cerebral melanoma or glioblastoma started at MIT 
[7,8]. At the end of the 1990s a similar research program started in Petten, the Netherlands, for 
cerebral tumours [9], and similar trials were initiated in Sweden and Finland [10,11]. In 2001 and 
2003 two patients affected by liver metastases were treated in Pavia with the auto-transplantation 
technique, which will be described in the next section [12,13]. In 2003 a trial for skin melanoma 
started in Argentina [14], and a trial for brain metastases was initiated in Petten. Analogous research 
works were developed in Czech Republic, South-Korea, Taiwan and Russia. At the moment the trials 
for brain tumours are going on mainly in Japan, together with a new research on lung. Lung tumours 
are now one of the most interesting targets for BNCT, and the activity in Pavia is currently focused on 
this organ. Concerning other tumour types, projects have been developed for liver (e.g. Argentina, 
Germany and Japan), head and neck cancers (e.g. Finland and Japan) and oral tumours, and other 
malignancies such as osteosarcoma are under evaluation. Particularly interesting seem the outcomes of 
a Finnish clinical trial on head and neck inoperable recurrences. Over the first 12 patients, with a 
median follow-up of 31 months, 10 responded to BNCT and 2 had tumour growth stabilization for 5.5 
and 7.6 months. The median duration of tumour control was 10 months, and the median survival time 
was 13 months. Three patients were alive at the time of the analysis (follow-up of 30, 31 and 36 
months), one of them without cancer recurrence and with a good quality of life [15].         
     After reporting on the clinical experience in Pavia for liver metastases, this paper will provide an 
overview of the main BNCT-related activities currently ongoing in Pavia (i.e. Boron concentration 
measurements, organ dose simulations in humans, animal irradiation and radiobiological studies), 
where the research is now focused on lung tumours. Lung carcinoma is indeed the main cause of  
cancer mortality worldwide; however, despite the recent introduction of new therapeutic agents, little 
progress has been achieved in terms of survival, and the prognosis for these patients remains poor. 
BNCT can therefore be a valid option for the treatment of diffuse lung tumours and lung metastases, 
which generally show a poor response to both surgery and chemotherapy. Among the various 
activities, particular attention will be devoted to computational radiobiology studies at sub-cellular and 
cellular level, for which a mechanistic model and a Monte Carlo code originally developed for 
chromosome aberration induction has been recently extended and applied to the simulation of tumour 
cell death following enrichment with 10B and thermal neutron irradiation like in a typical BNCT 
treatment.        
 
 
2 BNCT in Pavia: the clinical experience on liver with the auto-transplantation 
technique 
 
Within the TAOrMINA project, in December 2001 for the first time in the world an isolated liver 
affected by colon-carcinoma metastases, previously loaded with a 10B compound, was irradiated with 
thermal neutrons at the Triga Mark II reactor of the University of Pavia [12,13]. The procedure 
consisted of three main phases: 1) early surgical phase, including a 2-hours liver perfusion with a 
solution of 10boronophenylalanine (10BPA), two biopsies of both metastatic and normal hepatic tissue 
to verify a favourable (that is, higher than 4:1) 10B concentration ratio between the samples, and finally 
the hepatectomy with contemporary starting of an extra-corporeal circulation; 2) radiotherapeutic 
phase, during which the isolated liver was washed and chilled, transferred to the thermal column of the 
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reactor and irradiated isotropically for about 10 minutes; 3) late surgical phase, in which the liver was 
reconnected to the patient and the extra-corporeal bypass was removed. The patient was a 48-years-old 
man with 14 liver metastases, operated seven months before. The whole procedure lasted 21 hours, 
and the ratio between the 10B concentration in the tumour and that in the healthy tissue was close to 
6:1. In 2003 a second patient, a 39-years-old male affected by 11 hepatic metastases already operated, 
underwent the same procedure, which lasted 18 h 40‟. 
     The location for liver irradiation was built inside the thermal column of the reactor, where the  
background coming from the core was lowered by means of two bismuth screens (overall thickness = 
20 cm); the gamma dose was measured by BeO TLD dosimeters, whereas the neutron flux was 
measured by Au and Cu wires/foils (1.4x1010 thermal neutrons cm-2 s-1 in air). The Boron 
concentration was evaluated basing on alpha-particle spectrometry coupled to neutron auto-
radiography; more details on this method will be provided in the next section. With a neutron fluence 
of 4x1012 n cm-2,  for both patients the absorbed dose was 18 1 Gy in the tumour and 6 0.3 Gy in the 
healthy liver, whereas the 10B concentration ratio between tumour and healthy tissue was 5.9 for the 
first patient and 5.6 for the second one. For the irradiation, the liver was placed inside two Teflon bags 
and positioned in a Teflon container, which was transported to the irradiation channel by a semi-
automatic trolley. Halfway through the irradiation time, the Teflon container was rotated by 180  
using a remote control, to increase the uniformity of the thermal neutron flux distribution inside the 
organ. 
     During the first three weeks after the treatment, both patients were affected by a dramatic but 
totally reversible “post-irradiation syndrome”, mediated by the release of a large amount of cytokines 
as an effect of cellular necrosis. In the same period of time, a similar evolution of the liver lesions was 
observed for both patients, with necrotic areas appearing in the regions that were occupied by tumour 
nodules before the treatment. During the fourth week the clinical evolution of the two cases became 
different: while the second patient, who was suffering from a cardiomyopathy, died on the 33th p.o.d. 
following severe circulatory complications, the first one progressively returned to normal laboratory 
values (including neoplastic markers and the residual liver function) and was discharged after 40 days 
in a good state of health. Twenty months after BNCT a CT scan showed a tumour recurrence, which 
was removed surgically. Unfortunately, thirty-three months after BNCT multiple recurrences 
appeared, for which chemotherapy, immunotherapy and surgery resulted ineffective, leading to the 
patient death 44 months after the BNCT treatment. Such recurrences are likely to be due to cells that at 
the moment of irradiation were quiescent, thus non-proliferating and unable to uptake and retain 
adequate levels of BPA. This hypothesis was confirmed by experiments with in vitro cell cultures, 




3 BNCT in Pavia: ongoing research activities on lung tumours 
 
3.1 Boron  concentration measurements 
 
The selective killing of tumour cells, which is a fundamental requirement for any anti-cancer therapy, 
in BNCT can be achieved thanks to the selective uptake of 10B in tumour cells with respect to normal 
ones; a reliable 10B concentration measurement both in tumour tissues and in normal ones is therefore 
a crucial step in view of a BNCT treatment plan, in order to identify the conditions that will deliver a 
therapeutic dose to the tumour sparing the normal parenchyma. Many methods were developed to 
measure 10B concentrations in biological samples, including inductively coupled plasma atomic 
emission spectrometry (ICP-AES), ICP-mass spectrometry (ICP-MS), and prompt-gamma neutron 
activation analysis (PGNAA). [16]. Whatever method is used, it is essential to know what kind of 
tissues are present in the analysed samples, since tumour cells, normal cells and necrotic areas can be 
simultaneously present in a metastatic sample. This is the reason why in Pavia a quantitative approach 
based on alpha-particle spectrometry is coupled to a qualitative approach based on neutron 
autoradiography.  
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     The qualitative analysis [17] requires to cut couples of tissue sample slices; for each couple, the 
first slice (70 m thick) is deposited on a sensitive film for neutron autoradiography, whereas the 
second one (10 m thick) is deposited on glass for morphological analysis. The samples deposited on 
the films are irradiated with thermal neutrons, and the high-LET particles coming from the 10B(n, )7Li 
reaction induce latent tracks, which are visualized by etching. The protocol for lung samples consists 
of irradiating the films and then etching them in a NaOH solution. Figure 1 shows a comparison 
between a histological preparation and a neutronigraphic image of two subsequent tissue slices. 
     Concerning the quantitative analysis, the method applied in Pavia is based on the energy spectrum 
of the charged particles produced in the 10B(n, )7Li reaction [16,18]. Tissue samples treated with BPA 
are irradiated in the thermal column, in a position where the thermal neutron flux is of the order of 109 
cm-2 s-1 . Since the slices are 70 m thick, they are thicker than the range of the alpha particles. 
Therefore the energy spectra are not Gaussian peaks, and the determination of the 10B concentration 
requires a deep analysis including information on the stopping power of alpha particles in tissue. In 
addition to the alpha-particles and the 7Li ions originated by the 10B(n, )7Li reaction, protons from the 
14N(n,p)14C reaction are also present due to the Nitrogen atoms naturally contained in the cells. 
Selecting an energy window of 1110-1350 keV allows to discriminate against Nitrogen protons and 
7Li ions. The absolute 10B concentration (in parts per million or ppm, that is micrograms of Boron 
atoms per gram) is then calculated as: 
 
[10B]=KC E/( S ( x)) .                                                                                                                  (1) 
 
     K is a normalization constant, C represents the experimental counts in the energy range E,  is the 
geometrical efficiency of the apparatus,  is the microscopic cross section of the (n, ) reaction,  is 
the thermal neutron flux, S is the tissue sample surface seen by the detector through the collimator, 
and E/ ( x) is the alpha-particle stopping power in (dry) tissue. The experimental error associated to 
this method is of the order of 10%, and the lower limit of detection is about 0.5 ppm, due to the natural 
10B background in tissue. The main advantage of this method is the ability to measure the 10B 
concentration as well as the 10B distribution in a 2-D tissue slice, and to directly correlate the 
macroscopic spatial information to the histology of the analyzed specimen. Further details on this 
method can be found elsewhere [16,18]. 
 
 
Fig. 1: Comparison between the autoradiography and the histological preparation (standard hematoxilin-eosin 
staining) of two subsequent slices cut from a rat lung with induced metastases and treated with BPA. a) neutron 
autoradiogram, b) histology (enlargement: 10 x). The arrows indicate the tumour nodules, which are darker in 
the neutron autoradiogram because the boron concentration is higher in the tumour cells.  
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3.2 Simulation of human lung irradiation 
 
In Pavia the WIDEST1 research project, funded by INFN (National Institute of Nuclear Physics) and 
MIUR (Ministry of University and Scientific Research), is aimed to explore the possibility of 
irradiating the whole lung using external, collimated epithermal neutron beams, and BPA as a 10B 
carrier. This way the patient will not undergo the complicated auto-transplantation procedure, and the 
neutrons, thermalized in the first tissue layers, would not be much attenuated thanks to the lung low 
density (about 0.3 g/cm3). To verify whether a proper dose distribution can be obtained in the lung and 
to test whether the surrounding sensitive organs can be spared, a Monte Carlo simulation study was 
performed with the MCNP code (version 4c2) coupled to the ADAM anthropomorphic phantom, 
which was irradiated with two ideal neutron beams (antero-posterior and postero-anterior), mono-
energetic and collimated, with dimensions of 11 x 26 cm2. [19,20]. A schematic representation is 
reported in Fig. 2. While the thermal neutron flux obtained  with a thermal neutron source (0.0253 eV) 
resulted to be about three times higher at the body surface with respect to the lung, the thermal neutron 
flux obtained with a 1 keV epithermal source resulted to be very advantageous, being three times 
lower in the skin with respect to the lung and remaining uniform in the lung. Assuming a 10B 
concentration of 25 ppm in the tumour and 5 ppm in the healthy lung, the physical dose to the tumour 
resulted to be about two times the dose to the normal lung, mainly due to the relatively high gamma 
contribution. A ratio of about 3.5 was obtained considering only the contribution of the charged 
particles. However, the ratio between the dose in the tumour and that in the normal lung further 
increases up to 5 weighing the various dose components by the corresponding biological factors, that 
is the Relative Biological Effectiveness (RBE) and the Compound Biological Effectiveness (CBE). In 
particular, the dose delivered to normal lung following an irradiation of 15 minutes with a neutron flux 
of 1.75x109 neutrons/(cm2 s) would be 4 Gy-Eq in the central section of the lung, highly consistent 
with literature prescriptions on the lung tolerance doses. These results obtained with an ideal beam 
indicate that the treatment of lung tumours by multiple (external) epithermal neutron beams could be 
feasible, since the low density of the lung allows for a quite uniform dose distribution in the whole 





Fig. 2: ADAM model used as an input for MCNP to simulate the irradiation of the entire lung by collimated 
external epithermal neutron beams. The figure shows the irradiated region and the two opposite ideal beams used 
to calculate the dose delivered to each tissue. The 1 keV neutrons are perfectly collimated, and leave the spine 
outside the irradiation field  
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3.3 Animal irradiation 
 
An investigation on the in vivo BNCT effectiveness has been planned, consisting of the irradiation of 
rats affected by lung metastases in the thermal column of the Triga Mark II reactor of the University of 
Pavia. The rats will be inserted in a shielding box with a window for lung irradiation, with the main 
aim of proving that the tumour can be treated sparing the normal tissues, investigating the radiation-
induced changes in the lung histology, and verifying the increase of the animal surviving time. As a 
necessary step before starting the experiments, the MCNP code (version 4c2) was applied to the 
calculation of organ dose distributions in a rat model phantom [21], which was simulated as a cylinder 
with internal geometrical structures representing the various organs: skin (modelled as a 0.5 cm thick 
external cylinder), lungs, oesophagus, intestine, heart, spine, kidneys and brain, with the various 
materials defined according to ICRU-46; the lungs were divided into 0.125 cm3 cubic voxels, in order 
to obtain a detailed map of the dose absorbed in the region of interest. The rat model was inserted into 
different shielding boxes of variable shape and thickness, with different dimensions of the lung 
window; Fig. 3 shows a representation of the rat model simulated with MCNP. The following 
parameters were considered to evaluate the shielding effectiveness: tolerance doses in the healthy 
tissues, uniformity of the thermal neutron flux distribution in the lung, and dose-volume histogram 
(DVH) in the healthy lungs when delivering to the tumour a therapeutic dose of at least 40 Gy-Eq.  
     The simulations were validated by comparisons with measurements performed with a simplified rat 
model consisting of three polyethylene cylinders (body, neck and head) with a copper wire along their 
principal axis, inserted in a Teflon cylindrical box. The thermal neutron flux was measured with the 
activation method basing on the 63Cu(n, )64Cu radiative capture reaction, following 1h irradiation at 
250 kW perpendicularly to the longitudinal axis of the thermal column, which is a 1 m long channel 
with a section of 40x20 cm2. The simulations were in good agreement with the measured thermal 
neutron flux, both in air and in the phantom. The shielding configuration that best fulfilled the 
aforementioned criteria was a 1.5 cm thick cylindrical container filled with Lithium carbonate, with a 
4 cm window for lung irradiation; the box must be rotated by 180  halfway during the irradiation time. 
Under these conditions, the following results were obtained: 1) the calculated ratio between the 
maximum and the minimum thermal neutron flux in the lungs was 1.5, indicating a good uniformity; 
2) with a 10B concentration of 77 ppm in the tumour and 22 ppm in the normal lung, an irradiation 





Fig. 3: Longitudinal section of the rat model designed with MCNP geometry, with the neck and the body 
modelled as cylinders, and the head modelled as an elypsoid; the latticed cylinder inside the body represents the 
lungs, whereas the outer structure is the shielding box with a window for lung irradiation 
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     With this treatment plan, the doses to the considered normal tissues were lower than the tolerance 
doses with the only exception of the kidneys, for which an additional shielding can be considered; in 
particular, the mean dose to the normal lung was 5.9  Gy-Eq. The mean weighted dose to the tumour 
was 49 4 Gy-Eq, implying a ratio between dose to the tumour and dose to the healthy lung higher 
than 8. These results indicate that the rat irradiation in the thermal column is feasible, allowing to 
deliver a therapeutic dose to the tumour sparing the normal tissues in a time that is highly compatible 
with the anaesthesia. A shielding box with the characteristics described above has already been 
constructed, and the animal irradiation will start soon. 
 
3.4 Radiobiology: experiments and simulations  
To better understand the effects of a BNCT treatment down to the cellular level, in vivo and in vitro 
radiobiology studies are ongoing in Pavia since several years. While in vivo studies are focused on 
BD-IX rats [22], the in vitro activity is devoted to different tumour cells including DHDK12TRb 
(DHD) cells, a rat coloncarcinoma cell line that induces metastases either in the liver or in the lung, 
depending on the injection site. In particular the Boron uptake as a function of BPA concentration and 
time of treatment and the Boron washout as a function of temperature and time after BPA deprivation 
have been characterized in a recent work, as well as the survival of DHD cells following irradiation 
with either gamma rays, or thermal neutrons without previous Boron uptake, or thermal neutrons 
following Boron uptake. A detailed description can be found elsewhere [23]. 
     The in vitro cell survival studies have been recently integrated by an activity of computational 
radiobiology at sub-cellular and cellular level. More specifically, a mechanistic model and a Monte 
Carlo code originally developed for radiation-induced chromosome aberrations - that is incorrect 
rejoining of chromosome fragments - in normal cells have been extended to simulate the survival of 
DHD cells following enrichment with 10B and subsequent irradiation with thermal neutrons, like in a 
typical BNCT treatment. The model/code for chromosome aberration induction, which was initiated in 
1997 [24,25], relies on the following basic assumptions: 1) chromosome aberrations arise from DNA 
clustered lesions, each lesion giving rise to two independent chromosome free-ends; 2) only pairs of 
free ends created within a threshold distance d will join and thus take part in the process of aberration 
formation. These assumptions rely on the evidence that, on average, 1 Gy of (low-LET) radiation 
induces about 40 DNA double-strand breaks (DSBs) per cell, but less than 1 aberration per cell; it is 
therefore very likely that, among the many initially induced DNA breaks, only those that are severe 
enough (like clustered ones) and close enough are involved in DNA damage mis-repair and thus in the 
formation of chromosome aberrations. Up to now, the model has been validated for the induction of 
the main chromosome aberration types in normal lymphocytes exposed to X- or -rays [26], light ions 
such as protons and alpha particles [27], and heavier ions like Carbon, which is nowadays of great 
interest for tumour hadrontherapy, and Iron, interesting for space radiation research [28,29]. The 
agreement between simulations and literature experimental data supports the model assumptions on 
the mechanisms governing chromosome aberration induction, including the fundamental role of 
clustered DNA damage and the step-like distance dependence for the interaction probability between 
two (clustered) DNA lesions. Furthermore, the model has been applied to predict the induction of 
Chronic Myeloid Leukaemia following exposure to low-LET radiation [30] and the induction of 
chromosome aberrations in astronauts exposed to space radiation [31]. A detailed description of the 
simulation methods is beyond the scope of this paper, and can be found elsewhere [24-32]. 
     Basing on an experimental observation concerning the link between chromosome aberrations and 
cell death [33], the model was recently extended to simulate radiation-induced cell death adopting a 
one-to-one relationship between the average number of “lethal aberrations” (i.e., dicentrics, rings and 
deletions) per cell and –lnS, being S the fraction of surviving cells. More specifically, for each 
considered dose value D the fraction of surviving cells was calculated as S(D) = exp[-LA(D)], where 
LA(D) is the (simulated) average number of lethal aberrations (dicentrics+rings+deletions) per cell 
following a dose D. Although the observation by Cornforth and Bedford was specifically related to 
normal fibroblasts exposed to X rays, in the present work this approach was applied not only to low-
LET radiation but also to intermediate- and high-LET particles, both for normal cells and for tumour 
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ones. The starting point consisted of reproducing the experimental outcomes obtained by Cornforth 
and Bedford, that is survival of normal cells following X-ray irradiation. Figure 4 shows the simulated 
dose-response curve for cell survival obtained as described above, as well as the corresponding 
experimental data on AG1522 normal fibroblasts exposed to X rays; the agreement between 
simulations and data validates the model for the survival of normal cells exposed to X rays, and more 




Fig. 4: Survival of normal cells exposed to X rays; the line represents the model prediction, whereas the points 
are literature data for comparison taken from ref. [33].  
 
     As a second step, the same approach was applied to simulate the survival of normal cells exposed 
to intermediate and high LET radiation such as protons and alpha particles, which are both involved in 
BNCT. The simulation outcomes were compared with literature data on V79 cells exposed to either 
0.64 MeV protons [34], or 3.2 MeV alpha particles [35], corresponding to an average LET in water of 
35 keV/ m and 120 keV/ m, respectively (results not shown here); the agreement between 
simulations and data provided a validation of the model for the survival of normal cells exposed to a 
monochromatic, parallel field of protons or alpha particles. The final step of the present work 
consisted of extending the code to simulate the survival of tumour cells exposed to a BNCT treatment, 
that is enrichment with 10B and subsequent irradiation with thermal neutrons. Since in a Boron-rich 
tissue thermal neutrons deposit their energy mainly through the reactions 10B(n, )7Li and 14N(n,p)14C, 
where the energies of the involved particles are 1.47 MeV for alphas (corresponding to an average 
LET in water of ~190 keV/ m), 0.84 MeV for 
7
Li (~160 keV/ m) and 0.59 MeV for protons (~38 
keV/ m), in the simulations the irradiation was directly reproduced by means of alpha particles and 
protons; 7Li was treated like an alpha particle since the LET values of these particles are both quite 
high, thus implying no significant difference in terms of biological effectiveness. To reproduce a 
typical BNCT scenario, the code was purposely modified to allow the simulation of a mixed field of 
protons and alpha particles; furthermore, each particle was made start from a random position inside 
the cell with a random direction, to reproduce a uniform intra-cellular distribution of the 10B and 14N 
atoms. Figure 5 shows the simulated cell survival curves following exposure either to 0.59 MeV 
protons (to simulate thermal neutron irradiation of cells not enriched with 10B), or to a mixed field of 
1.47 MeV alpha particles and 0.59 MeV protons, to simulate thermal neutron irradiation of boron-
enriched cells. The experimental data reported for comparison are relative either to DHD cells exposed 
to thermal neutrons (but not pre-treated with 10B), or to DHD cells enriched with 10B and subsequently 
exposed to thermal neutrons [23]. 




Fig. 5: Fraction of surviving DHD cells following either exposure to thermal neutrons without 10B pre-treatment 
(upper curve), or enrichment with 10B and subsequent exposure to thermal neutrons (lower curve). The lines 
represent model predictions, whereas the points are experimental data taken from ref. [23].  
 
 
4 Concluding remarks 
 
After a brief introduction on some historical and clinical aspects of BNCT, the state of the art of the 
main activities ongoing in Pavia was presented. Such activities, which are currently focused on lung 
BNCT research, include Boron concentration measurements by neutron autoradiography and alpha 
spectrometry, organ dose simulations with the MCNP code and radiobiology studies, both 
experimental and theoretical. While the organ dose simulations indicate that the treatment of lung 
tumours by external neutron beams (epithermal for humans and thermal for rats) could be feasible, 
radiobiology studies are mainly aimed to the quantification of cellular Boron uptake and washout, as 
well as the characterization of cell death following enrichment with 10B and neutron irradiation.  
     Cell death was investigated not only experimentally but also theoretically, purposely extending a 
Monte Carlo code originally developed for radiation-induced chromosome aberrations. The agreement 
between simulations and cell survival data provided a validation of the model; a possible future 
development for this kind of activity is the evaluation of (non-lethal) damage in normal cells, which is 
an important issue not only for BNCT but for any tumour treatment. 
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